Skip to Content
Skip to Content

Substance evaluation - CoRAP

Substance evaluation - CoRAP

For each substance, the table shows the evaluating Member State, the year of evaluation and a short description of the concern which led to it being placed on the list.

Community rolling action plan (CoRAP): The community rolling action plan covers three consecutive years and is updated mid of March every year. From this it follows that substances in the table below with the column ‘Year’ indicating a current or future year, are those that have been prioritised for evaluation, and are effectively on the current CoRAP.

Documents to do with substance evaluation are also available here. They include: documents justifying selection of the substances, decisions to request more information. Member States' conclusions and Member States' final evaluation reports are included for substances for which evaluation has been finalised.

 

Notes to the Substance Evaluation and CoRAP table
  • Where two Members States are indicated, this is a joint evaluation. The first Member State mentioned leads the Evaluation and is the responsible competent authority in the meaning of Article 45(2) of REACH.
  • The substance public name is used. In most of the cases it is the name as disseminated on the ECHA website.
  • When the EC Number is not available, the number assigned to substance by ECHA after the inquiry process is used.
  • When the substances are included in the CoRAP, they have not yet been evaluated and thus the concern is indicative and not exhaustive or conclusive.
  • Contact details of the evaluating Member States are provided for all the substance included.
  • Please note that the justification document explains the grounds of the initial concerns that triggered the inclusion of the substance in the CoRAP for further clarification under substance evaluation. The justification document is based on a preliminary screening of the substance and is without prejudice to the outcome of the substance evaluation.

Legend:

  • Suspected PBT/vPvB: Potentially Persistent, Bioaccumulative and Toxic/very Persistent and very Bioaccumulative.
  • CMR: generic term for known carcinogenic and/or mutagenic and/or reprotoxic properties (according to CLP harmonised or registrant self-classification or CLP Inventory). The concern can refer to C, M, R or a combination of those.
  • Suspected CMR: generic term for suspected carcinogenic and/or mutagenic and/or reprotoxic properties (not classified according to CLP harmonised or registrant self-classification). The concern can refer to (suspected) C, M, R or a combination of those.
  • Sensitiser: generic term for known sensitising properties (according to CLP harmonised or registrant self-classification or CLP Inventory).
  • Suspected sensitiser: generic term for suspected sensitising properties (not classified according to CLP harmonised or registrant self-classification).
  • RCR: Risk Characterisation Ratio
Last updated 13 December 2019. Database contains 375 unique substances/entries.
Filter the list
Initial grounds for concern:

 
233-047-2
10025-91-9
2018
Germany
Suspected Carcinogenic
Suspected Reprotoxic
Concluded
Details
201-983-0
90-30-2
2012
Germany
Suspected PBT/vPvB
Wide dispersive use
Information requested
Details
931-745-8
-
2014
Sweden
Suspected PBT/vPvB
Exposure of environment
High RCR
Ongoing
Details
202-653-9
98-29-3
2018
Poland
Suspected Mutagenic
Potential endocrine disruptor
Suspected PBT/vPvB
Sensitiser
Exposure of environment
Exposure of workers
Concluded
Details
295-835-2
92129-33-4
2015
Italy
Exposure of environment
High (aggregated) tonnage
Other exposure/risk based concern
Wide dispersive use
Concluded
Details
310-154-3
121158-58-5
2018
Germany
Potential endocrine disruptor
Concluded
Details
203-584-7
108-45-2
2018
Latvia
Suspected Reprotoxic
Sensitiser
Exposure of workers
High (aggregated) tonnage
Concluded
Details
202-510-0
96-49-1
2018
Latvia
Suspected Reprotoxic
Other hazard based concern
Consumer use
Exposure of workers
High (aggregated) tonnage
Wide dispersive use
Concluded
Details
1 - 4.5 moles propoxylated
500-097-4
37353-75-6
2013
Denmark
Suspected CMR
High (aggregated) tonnage
Wide dispersive use
Conclusion under preparation
Details
200-889-7
75-65-0
2013
United Kingdom
Suspected CMR
Consumer use
High (aggregated) tonnage
High RCR
Wide dispersive use
Concluded
Details
266-733-5
67584-55-8
2018
Germany
Suspected PBT/vPvB
Other hazard based concern
Exposure of environment
Wide dispersive use
Concluded
Details
202-597-5
97-63-2
2014
Italy
Suspected CMR
Sensitiser
Consumer use
High (aggregated) tonnage
Wide dispersive use
Concluded
Details
700-992-1
-
2014
Norway
Suspected PBT/vPvB
Consumer use
High (aggregated) tonnage
Wide dispersive use
Ongoing
Details
262-975-0
61788-44-1
2014
Germany
Potential endocrine disruptor
Suspected PBT/vPvB
Cumulative exposure
Ongoing
Details
254-052-6
38640-62-9
2013
Sweden
Suspected PBT/vPvB
High (aggregated) tonnage
Wide dispersive use
Information requested
Details
215-222-5
1314-13-2
2017
Germany
Other hazard based concern
Consumer use
Exposure of environment
Other exposure/risk based concern
Wide dispersive use
Information requested
Details
204-127-4
116-15-4
2015
Italy
Suspected CMR
High (aggregated) tonnage
Ongoing
Details
203-475-4
107-25-5
2018
Latvia
Suspected Reprotoxic
Consumer use
Exposure of sensitive populations
Exposure of workers
Other exposure/risk based concern
Concluded
Details
216-823-5
1675-54-3
2015
Denmark
Suspected CMR
Potential endocrine disruptor
Consumer use
High (aggregated) tonnage
Wide dispersive use
Follow-up
Details
205-480-7
141-32-2
2013
Sweden
Suspected CMR
High (aggregated) tonnage
Other exposure/risk based concern
Conclusion under preparation
Details
202-163-5
92-52-4
2013
Portugal
Suspected PBT/vPvB
High (aggregated) tonnage
Conclusion under preparation
Details
202-425-9
95-50-1
2013
Hungary
Suspected CMR
High (aggregated) tonnage
Wide dispersive use
Conclusion under preparation
Details
432-240-0
12056-51-8
2017
France
Carcinogenic
Exposure of workers
Information requested
Details
253-775-4
38083-17-9
2014
Belgium
Suspected CMR
Consumer use
Wide dispersive use
Information requested
Details
200-262-8
56-23-5
2012
France
CMR
Exposure of workers
High (aggregated) tonnage
Conclusion under preparation
Details
202-532-0
96-76-4
2017
Belgium
Suspected CMR
Potential endocrine disruptor
Consumer use
Wide dispersive use
Information requested
Details
700-242-3
62037-80-3
2017
Germany
Suspected PBT/vPvB
Exposure of environment
Information requested
Details
264-120-7
63393-96-4
2017
Italy
Suspected PBT/vPvB
Exposure of environment
High RCR
Wide dispersive use
Information requested
Details
202-908-4
101-02-0
2013
United Kingdom
Suspected CMR
Potential endocrine disruptor
Sensitiser
Consumer use
High (aggregated) tonnage
Wide dispersive use
Concluded
Details
205-739-4
149-44-0
2021
Netherlands
Suspected Carcinogenic
Suspected Mutagenic
Suspected Reprotoxic
Exposure of workers
High (aggregated) tonnage
Wide dispersive use
Not started
Details
231-836-6
7758-19-2
2019
Hungary
Suspected Mutagenic
Suspected Reprotoxic
Exposure of workers
Wide dispersive use
Ongoing
Details
204-500-1
121-82-4
2020
Hungary
Suspected Carcinogenic
Suspected Reprotoxic
Exposure of environment
Exposure of workers
Wide dispersive use
Not started
Details
203-497-4
107-51-7
2015
Norway
Suspected PBT/vPvB
Consumer use
Wide dispersive use
Follow-up
Details
220-260-0
2691-41-0
2020
Hungary
Suspected Carcinogenic
Suspected Reprotoxic
Exposure of environment
Exposure of workers
Wide dispersive use
Not started
Details
209-909-9
597-82-0
2016
Netherlands
Suspected PBT/vPvB
Information requested
Details
211-063-0
628-96-6
2016
Italy
Suspected Reprotoxic
Potential endocrine disruptor
Suspected PBT/vPvB
Suspected Sensitiser
High (aggregated) tonnage
Wide dispersive use
Follow-up
Details
248-948-6
28299-41-4
2014
Netherlands
Suspected PBT/vPvB
High (aggregated) tonnage
Follow-up
Details
205-491-7
141-62-8
2015
Norway
Suspected PBT/vPvB
Exposure of environment
Wide dispersive use
Follow-up
Details
202-046-9
91-17-8
2012
Finland
Suspected PBT/vPvB
High (aggregated) tonnage
Follow-up
Details
200-843-6
75-15-0
2013
France
CMR
Potential endocrine disruptor
Exposure of environment
Exposure of workers
High (aggregated) tonnage
Follow-up
Details
251-020-3
32388-55-9
2021
Netherlands
Potential endocrine disruptor
Suspected PBT/vPvB
Not started
Details
264-727-7
64194-22-5
2021
Slovenia
Suspected Carcinogenic
Exposure of workers
Wide dispersive use
Not started
Details
248-227-6
27107-89-7
2021
Netherlands
Potential endocrine disruptor
Not started
Details
204-317-7
119-36-8
2015
France
Suspected CMR
Consumer use
High (aggregated) tonnage
Follow-up
Details
203-312-7
105-59-9
2013
United Kingdom
Suspected CMR
High (aggregated) tonnage
High RCR
Wide dispersive use
Concluded
Details
239-701-3
15625-89-5
2014
France
Sensitiser
Exposure of workers
High RCR
Wide dispersive use
Concluded
Details
905-806-4
-
2015
Estonia
CMR
Suspected PBT/vPvB
Sensitiser
Consumer use
High (aggregated) tonnage
Wide dispersive use
Concluded
Details
430-050-2
-
2017
Spain
Suspected PBT/vPvB
Exposure of environment
Wide dispersive use
Concluded
Details
246-677-8
25155-23-1
2014
Italy
Exposure of environment
Exposure of workers
High (aggregated) tonnage
High RCR
Suspected PBT/vPvB
Wide dispersive use
Follow-up
Details
205-201-9
135-57-9
2014
Belgium
Suspected PBT/vPvB
Exposure of environment
Conclusion under preparation
Details

Export search results to:

Categories Display

Tagged as:

(click the tag to search for relevant content)


Route: .live2